• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

Acute Leukemia Endpoints Agenda

Presented by the American Society of Hematology and the U.S. Food and Drug Administration
Co-sponsored by the American Association for Cancer Research, American Society of Clinical Oncology, and Southwest Oncology Group

Friday, June 24, 2005
8:30 a.m. – 5:00 p.m.
JW Marriott Hotel Pennsylvania Avenue
Salons F and E
1331 Pennsylvania Avenue, Washington, DC 20004
Ph: (202) 393-2000


8:00 am
Continental Breakfast Available
Registration for Public Comments
8:30 am Welcome and Introductions Stanley L. Schrier, MD
    Richard Pazdur, MD
8:40 am Purpose of Conference & Regulatory Background   Nancy Scher, MD
9:00 am Scope and Background of Panel Frederick Appelbaum, MD
9:10 am  Scope of Problem/Heterogeneity Component Frederick Appelbaum, MD
9:30 am Panel Questions regarding Heterogeneity Panel
9:50 am Break  
10:00 am Definition of Response Component Susan O’Brien, MD
10:20 am Panel Questions regarding Definition of Response Panel
10:40 am Minimal Residual Disease Component William L. Carroll, MD
11:00 am Panel Questions regarding Minimal Residual Disease Panel
11:20 am Bridge to Transplant Component Robert J. Arceci, MD
11:40 am Panel Questions regarding Bridge to Transplant Panel
12:00 pm Lunch Available for all Registered Participants (Garden Terrace)



1:00 pm Quality of Life Component Philip Breitfeld, MD
1:20 pm Panel Questions regarding Quality of Life Panel
1:40 pm Public Comments  
2:10 pm Chairs’ Questions to Panel Frederick Appelbaum, MD
Daniel Rosenblum, MD